tm logo
FIDALTO
Live/Pending
FIFTH EXTENSION - GRANTED

granted

on 04 Jan 2023

Last Applicant/ Owned by

400 Interpace Parkway

Parsippany

NJ

07054

Serial Number

88728509 filed on 16th Dec 2019

Registration Number

N/A

Correspondent Address

Teva Pharmaceuticals USA, Inc.

Building A

400 INTERPACE PARKWAY

PARSIPPANY NJ 07054

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

FIDALTO

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and tRead More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Mark Details


Serial Number

No 88728509

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
05th Jan 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04th Jan 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
04th Jan 2023SOU EXTENSION 5 GRANTED
14th Dec 2022TEAS EXTENSION RECEIVED
14th Dec 2022SOU EXTENSION 5 FILED
17th Jun 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15th Jun 2022TEAS EXTENSION RECEIVED
15th Jun 2022SOU EXTENSION 4 FILED
15th Jun 2022SOU EXTENSION 4 GRANTED
15th Dec 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED